SCHEMBL24359484

SCHEMBL24359484

CC(C)N(C)CCCCCCC(=O)Nc1nc2ccccc2s1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.67
▸ HDAC1 Q13547 4/20 0.66
▸ HDAC6 Q9UBN7 3/20 0.66
▸ HDAC2 Q92769 2/20 0.66
▸ HDAC8 Q9BY41 2/20 0.66
▸ HDAC3 O15379 1/20 0.66
▸ HDAC4 P56524 1/20 0.66
▸ HDAC7 Q8WUI4 1/20 0.66
▸ HDAC10 Q969S8 1/20 0.66
▸ HDAC11 Q96DB2 1/20 0.66
▸ HDAC9 Q9UKV0 1/20 0.66
▸ HDAC5 Q9UQL6 1/20 0.66
▸ TSHR P16473 1/20 0.59
▸ POLB P06746 1/20 0.58
▸ KLF5 Q13887 1/20 0.56
▸ MAPK1 P28482 5/20 0.54
▸ ALDH1A1 P00352 4/20 0.54
▸ CSNK1D P48730 2/20 0.53
▸ NCS1 P62166 1/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31158400 0.84 MAPT (0.49) MAPTHDAC1HDAC6HDAC2HDAC8
SCHEMBL24359481 0.84 MAPT (0.49) MAPTHDAC1HDAC6HDAC2HDAC8
SCHEMBL27622427 0.82 MAPT (0.77) MAPTHDAC1HDAC6HDAC2HDAC8
SCHEMBL20369717 0.82 MAPT (0.77) MAPTHDAC1HDAC6HDAC2HDAC8
SCHEMBL3239389 0.81 POLB (0.82) MAPTHDAC1HDAC6HDAC2HDAC8
SCHEMBL8234055 0.81 HDAC1 (0.79) MAPTHDAC1HDAC6HDAC2HDAC8
SCHEMBL10695859 0.81 MAPT (0.75) MAPTHDAC1HDAC6HDAC2HDAC8
SCHEMBL3237781 0.80 MAPT (1.00) MAPTHDAC1HDAC6HDAC2HDAC8
SCHEMBL24359688 0.80 MAPT (0.67) MAPTHDAC1HDAC6HDAC2HDAC8
SCHEMBL6227275 0.80 MAPT (0.73) MAPTHDAC1HDAC6HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240327427-A1 NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2024-10-03 — — US disclosed
WO-2022087456-A1 NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2022-04-28 — — WO disclosed
WO-2022087456-A1 NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2022-04-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327427-A1 NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE PSEN2, PSEN1, CHAT MAPT 13/4885HDAC1 1254/4885HDAC6 441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback